Are GLP-1s becoming ‘whole-body medicines’? What the evidence supports

What the source reports

The pharmaceutical industry increasingly describes GLP-1 and related incretin medicines as part of a broader metabolic-health platform. That reflects genuine expansion beyond blood glucose and body weight, but ‘whole-body medicine’ is not a regulatory or scientific drug category.

The evidence sits at very different levels. Particular products now have defined US indications involving cardiovascular risk, chronic kidney disease associated with type 2 diabetes, and metabolic dysfunction-associated steatohepatitis, known as MASH. Asthma and addiction are research questions, while two major Alzheimer’s trials produced a negative result.

It is therefore inaccurate to say that GLP-1 drugs as a class treat all these conditions. The medicine, formulation, dose, patient group, outcome and country all matter.

First rung: cardiovascular disease has established evidence

In March 2024, the US Food and Drug Administration approved Wegovy injection to reduce cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and either obesity or overweight. This was the first cardiovascular-risk indication specifically for a weight-management medicine.

The indication does not mean semaglutide prevents heart disease in everyone. The pivotal population already had cardiovascular disease, and the approved wording belongs to a particular Wegovy product and population.

Cardiovascular benefit is one reason ‘weight-loss drug’ can now be an incomplete description. It is not a reason to treat every cardiovascular condition with every GLP-1 medicine.

Second rung: kidney and liver uses are real but tightly defined

The current US Ozempic label includes reducing the risk of sustained kidney-function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That is not an indication for all kidney disease, including disease unrelated to type 2 diabetes.

In August 2025, the FDA granted accelerated approval to Wegovy injection for adults with MASH and moderate-to-advanced liver fibrosis. Accelerated approval was based on improvement in liver-biopsy measures while a longer trial continues to test whether this translates into fewer clinical liver outcomes.

These approvals support a broader metabolic-health view because diabetes, obesity, cardiovascular disease, kidney disease and MASH often overlap. They also show why product-specific wording matters: evidence for one defined use cannot simply be transferred across the entire class.

Asthma: an active proof-of-concept trial, not a treatment

The GATA-3 study is testing weekly semaglutide against placebo in adults with obesity-related symptomatic asthma. It is a single-site Phase 2 proof-of-concept trial with an estimated 100 participants.

ClinicalTrials.gov listed the study as active but not recruiting on 4 August 2026, with primary completion estimated for September 2026 and no results posted. Its investigators are measuring asthma control and markers of airway inflammation.

Until results are available and replicated, semaglutide should not be described as an asthma treatment. Any improvement would also need analysis to distinguish effects related to weight loss from other possible airway or inflammatory mechanisms.

Addiction: encouraging signals, but still early

Randomised trials have begun testing semaglutide in alcohol use disorder. A small US trial reported reductions in drinks per drinking day and craving, but not in average drinks per calendar day or the number of drinking days. A separate 26-week Danish trial studied 108 people with alcohol use disorder and obesity alongside cognitive behavioural therapy.

These results are more informative than anecdotes, but they do not establish semaglutide as a general addiction medicine. The studies involve selected populations, different doses and relatively short follow-up, and research into alcohol use disorder does not automatically apply to nicotine, opioids or other substance-use disorders.

No semaglutide or GLP-1 product is approved specifically to treat alcohol or another substance-use disorder. Established addiction care should not be replaced by off-label self-treatment.

Alzheimer’s disease: the major counterexample

Novo Nordisk tested oral semaglutide in the Phase 3 evoke and evoke+ trials after earlier observational and biological findings suggested possible benefit. Together, the trials enrolled 3,808 adults with early symptomatic Alzheimer’s disease.

In November 2025, the company reported that semaglutide did not significantly slow Alzheimer’s progression compared with placebo on the primary clinical measure. The programme was terminated.

This result is central to the whole-body discussion. A medicine can affect weight, glucose, inflammation or cardiovascular risk without becoming an effective treatment for every disease connected to those systems.

Why one pathway can appear across many organs

Metabolic health is not confined to a single organ. Blood glucose, blood pressure, circulating lipids, body fat, inflammation, sleep and vascular function can influence the heart, liver, kidneys, lungs and brain. Improving one upstream factor can therefore change several downstream outcomes.

Researchers are also studying possible effects beyond weight loss, including receptor signalling, appetite and reward pathways, inflammation and energy balance. The contribution of each mechanism may differ by medicine and condition.

That connected biology makes broad research reasonable. It does not prove that every observed association is a direct drug effect, or that one medicine should be prescribed for multiple unapproved purposes.

What remains uncertain

Many trials were designed around one product and a narrowly defined population. We still need longer follow-up, independent replication and direct comparisons to understand which benefits are caused by weight loss, improved metabolic risk factors or other biological effects.

Commercial language can also run ahead of clinical evidence. ‘Whole-body’ may communicate the breadth of research, but it can obscure negative trials, adverse effects, treatment discontinuation and the difference between an approved indication and an exploratory endpoint.

The most defensible interpretation is that selected GLP-1 and related medicines have become multi-indication metabolic treatments—not universal medicines for the whole body.

What this means for OurGLP1 users

Tracking should preserve the purpose of treatment as well as the product, formulation, dose and schedule. A medicine used for type 2 diabetes, weight management, cardiovascular-risk reduction or another approved indication may require different context even when the active ingredient is the same.

It can also be useful to record observations by domain—such as weight, glucose, blood pressure, sleep, symptoms and quality of life—without treating an app-generated pattern as proof of a medical benefit or side effect.

An app can support recall and a better clinical conversation. It cannot diagnose a new condition, confirm that a medicine caused a change, or expand the approved purpose of a prescription.

Bottom line

GLP-1 medicines are no longer accurately described only as diabetes or weight-loss drugs. Certain products now have evidence-backed cardiovascular, kidney and liver uses, while several other organ systems are under study.

But the evidence is uneven: asthma and addiction remain experimental, and the large Alzheimer’s programme failed. ‘Whole-body medicine’ is best treated as shorthand for an expanding research and regulatory landscape—not as a promise that GLP-1 medicines treat the whole body.